# EDGAR Filing Document

**Accession Number:** 0001665650
**File Stem:** 0000950103-26-005893
**Filing Date:** 2026-4
**Character Count:** 8690
**Document Hash:** 62d293296d273aebbdc307a74f9c2fa7
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000950103-26-005893.hdr.sgml**: 20260417

**ACCESSION NUMBER**: 0000950103-26-005893

**CONFORMED SUBMISSION TYPE**: 424B3

**PUBLIC DOCUMENT COUNT**: 3

**FILED AS OF DATE**: 20260417

**DATE AS OF CHANGE**: 20260417

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** JPMORGAN CHASE & CO
- **CENTRAL INDEX KEY:** 0000019617
- **STANDARD INDUSTRIAL CLASSIFICATION:** NATIONAL COMMERCIAL BANKS [6021]
- **ORGANIZATION NAME:** 02 Finance
- **EIN:** 132624428
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 424B3
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-293684
- **FILM NUMBER:** 26872377

**BUSINESS ADDRESS:**
- **STREET 1:** 270 PARK AVENUE
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10017
- **BUSINESS PHONE:** 2122706000

**MAIL ADDRESS:**
- **STREET 1:** 270 PARK AVENUE
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10017

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** J P MORGAN CHASE & CO
- **DATE OF NAME CHANGE:** 20010102

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CHASE MANHATTAN CORP /DE/
- **DATE OF NAME CHANGE:** 19960402

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CHEMICAL BANKING CORP
- **DATE OF NAME CHANGE:** 19920703
**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** JPMorgan Chase Financial Co. LLC
- **CENTRAL INDEX KEY:** 0001665650
- **STANDARD INDUSTRIAL CLASSIFICATION:** NATIONAL COMMERCIAL BANKS [6021]
- **ORGANIZATION NAME:** 02 Finance
- **EIN:** 475462128
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 424B3
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-293684-01
- **FILM NUMBER:** 26872378

**BUSINESS ADDRESS:**
- **STREET 1:** 383 MADISON AVENUE
- **STREET 2:** FLOOR 21
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10179
- **BUSINESS PHONE:** (212) 270-6000

**MAIL ADDRESS:**
- **STREET 1:** 383 MADISON AVENUE
- **STREET 2:** FLOOR 21
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10179

---

| | |
|:---|:---|
| **Prospectus addendum**<br> *To the prospectus dated April 17, 2026 and<br> the prospectus supplement dated April 17, 2026* | **Registration Statement Nos. 333-293684 and 333-293684-01<br> Dated April 17, 2026<br> Rule 424(b)(3)** |
| **JPMorgan Chase & Co.** | **JPMorgan Chase Financial Company LLC**<br>|

---

JPMorgan Chase & Co. and JPMorgan Chase Financial Company LLC have filed a prospectus dated April 17, 2026 (the "**Prospectus**") and a prospectus supplement dated April 17, 2026 (the "**Prospectus Supplement**") with the Securities and Exchange Commission. With respect to each preliminary pricing supplement dated prior to the date of this prospectus addendum relating to an offering with a pricing date after the date of this prospectus addendum (each, a "**Preliminary Pricing Supplement**"):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· all references to the prospectus of JPMorgan Chase & Co. and JPMorgan
Chase Financial Company LLC dated April 13, 2023 (the "**Original Prospectus**") (or to any section of the Original Prospectus)
are deemed to refer instead to the Prospectus (or to the corresponding section of the Prospectus); and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· all references to the prospectus supplement of JPMorgan Chase & Co. and
JPMorgan Chase Financial Company LLC dated April 13, 2023 (the "**Original Prospectus Supplement**") (or to any section
of the Original Prospectus Supplement) are deemed to refer instead to the Prospectus Supplement (or to the corresponding section of the
Prospectus Supplement), *provided* that any discussion in connection with tax treatment or tax consequences of notes in the Prospectus
Supplement shall be disregarded.

JPMorgan Chase & Co. and JPMorgan Chase Financial Company LLC have also filed the product supplements set forth under the heading "Replacement Product Supplement" in the table below (each, a "**Replacement Product Supplement**") with the Securities and Exchange Commission. With respect to each Preliminary Pricing Supplement, all references to any product supplement set forth under the heading "Original Product Supplement" in the table below (each, an "**Original Product Supplement**") (or to any section of that Original Product Supplement) are deemed to refer instead to the relevant Replacement Product Supplement (or to the corresponding section of that Replacement Product Supplement) as set forth in the table below.

---

| | |
|:---|:---|
| **Original Product Supplement** | **Replacement Product Supplement** |
| Product supplement no. 1-I dated April 13, 2023 | Transition product supplement no. 1-I dated April 17, 2026 |
| Product supplement no. 2-I dated April 13, 2023 | Transition product supplement no. 2-I dated April 17, 2026 |
| Product supplement no. 3-I dated April 13, 2023 | Transition product supplement no. 3-I dated April 17, 2026 |
| Product supplement no. 4-I dated April 13, 2023 | Transition product supplement no. 4-I dated April 17, 2026 |
| Product supplement no. UBS-1-I dated April 13, 2023 | Transition product supplement no. UBS-1-I dated April 17, 2026 |
| Product supplement no. WF-1-I dated April 13, 2023 | Transition product supplement no. WF-1-I dated April 17, 2026 |
| Product supplement no. 7-I dated December 19, 2023 | Product supplement no. 5-I dated April 17, 2026 |

---

In addition, JPMorgan Chase & Co. and JPMorgan Chase Financial Company LLC have filed the underlying supplements set forth under the heading "Replacement Underlying Supplement" in the table below (each, a "**Replacement Underlying Supplement**") with the Securities and Exchange Commission. With respect to each Preliminary Pricing Supplement, all references to any underlying supplement set forth under the heading "Original Underlying Supplement" in the table below (each, an "**Original Underlying Supplement**") (or to any section of that Original Underlying Supplement) are deemed to refer instead to the relevant Replacement Underlying Supplement (or to the corresponding section of that Replacement Underlying Supplement) as set forth in the table below.

---

| | |
|:---|:---|
| **Original Underlying Supplement** | **Replacement Underlying Supplement** |
| Underlying supplement no. 1-I dated April 13, 2023 | Underlying supplement no. 1-I dated April 17, 2026 |
| Underlying supplement no. 2-IV dated October 20, 2023 | Underlying supplement no. 2-I dated April 17, 2026 |
| Underlying supplement no. 5-IV dated January 14, 2026 | Underlying supplement no. 5-I dated April 17, 2026 |
| Underlying supplement no. 6-I dated April 13, 2023 | Underlying supplement no. 6-I dated April 17, 2026 |
| Underlying supplement no. 14-I dated April 13, 2023 | Underlying supplement no. 14-I dated April 17, 2026 |
| Underlying supplement no. 17-I dated April 13, 2023 | Underlying supplement no. 17-I dated April 17, 2026 |

---

---

| | |
|:---|:---|
| **Original Underlying Supplement** | **Replacement Underlying Supplement** |

---

---

| | |
|:---|:---|
| Underlying supplement no. 19-I dated April 13, 2023 | Underlying supplement no. 19-I dated April 17, 2026 |
| Underlying supplement no. 20-I dated July 31, 2023 | Underlying supplement no. 20-I dated April 17, 2026 |
| Underlying supplement no. 22-I dated May 12, 2023 | Underlying supplement no. 22-I dated April 17, 2026 |
| Underlying supplement no. 23-I dated August 28, 2023 | Underlying supplement no. 23-I dated April 17, 2026 |
| Underlying supplement no. 24-I dated September 1, 2023 | Underlying supplement no. 24-I dated April 17, 2026 |
| Underlying supplement no. 25-I dated February 15, 2024 | Underlying supplement no. 25-I dated April 17, 2026 |
| Underlying supplement no. 27-I dated March 18, 2025 | Underlying supplement no. 27-I dated April 17, 2026 |
| Underlying supplement no. 28-I dated June 4, 2025 | Underlying supplement no. 28-I dated April 17, 2026 |

---

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of the notes or passed upon the accuracy or the adequacy of this prospectus addendum or any Preliminary Pricing Supplement, Replacement Product Supplement, Replacement Underlying Supplement, the Prospectus Supplement or the Prospectus. Any representation to the contrary is a criminal offense.

***The notes are not bank deposits, are not insured by the Federal Deposit Insurance Corporation or any other governmental agency and are not obligations of, or guaranteed by, a bank.***

![](image_001.jpg)

April 17, 2026

### Attached PDF Documents

**Attachment 1:** `crt_dp245098-424b3pae.pdf`

_No text found in this document._